drugset / Trial / NCT01803087

Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients

NCT01803087

Phase 2 Completed 60 enrolled Chiesi Farmaceutici S.p.A.
RandomizedCrossoverOpen-labelTreatment

Summary

This clinical pharmacology want to investigate the systemic availability of BDP/B17MP (active metabolite of BDP) and formoterol after single oral inhalation of CHF 1535 100/6 pMDI with and without spacer device (AeroChamber Plus™) and in comparison to a free combination of BDP pMDI plus formoterol pMDI licensed products; this will be additionally compared to the systemic exposure in adults without the spacer device.

Timeline

Start
2012-02
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Formoterol Other / unclassified 24 ug Inhaled
Comparator beclomethasone dipropionate Other / unclassified 400 ug Inhaled

Indications